We harness deep learning on multi-omics data to model cells and efficiently engineer their behavior

Cells are the most advance piece of engineering on earth resulting from trillions of chemical interactions. However, small perturbations within those interactions, due to mutations or external influences, can lead cells to pathological states, then causing diseases.


For decades, biologists have struggled identify those causes by iteratively reconstructing cell mechanisms.


At DeepLife, we develop novel approaches based on state-of the art multi-omics data, machine learning, and systems engineering to identify molecular triggers driving back a cell in its healthy state.

We believe AI augmented bio-engineering

will design the cures of tomorrow


Our team’s DNA is encoded with 4 letters: Ambitious, Creative, Talented & Goal-oriented people

Jonathan Baptista
Co-founder & CEO

Graduated from Ecole Centrale de Paris with more than 7 years in system engineering and mathematical modeling. He has extensive experience in designing tools for complex systems simulation as well as leading deep tech projects for start-up and large companies

Jonathan Baptista
Co-founder & CEO
Jean-Baptiste Morlot
Co-founder & CTO

Passionate about sciences, he has always searched for tools to model the complexity of nature. After a master 2 in fundamental Physics, he pursued a PhD in machine learning applied genetics from University Pierre Marie Curie during which he published 5 peer review papers

Jean-Baptiste Morlot
Co-founder & CTO
We are hiring!
Find out more

We are looking for women and men willing to master state-of-the-art technology to tackle the biggests challenges of biology with direct application for patients

We are hiring!
Find out more


You want to supercharge your drug pipeline or just want to learn more about partnership opportunities, drop us your email:



    Read more about today solutions and be informed first

    How AI is transforming drug discovery, development and innovation

    For the first time in human history, our ability to collect data on our biology has outpaced our ability to interpret and act […]

    Outsourced drug discovery market to top $68bn in 2028

    The global drug discovery market is expected to reach $68bn in 2028, according to a Visiongain report, with revenue gains driven by flexibility, […]

    Many cancer drugs aim at the wrong molecular targets

    Many experimental cancer drugs might be succeeding in unintended ways, finds a study that used CRISPR–Cas9 gene editing to investigate how such drugs […]

    The Past, Present and Future of Genome Sequencing

    The last two decades have seen a revolution in genome sequencing with dramatic increases in speed and efficiency coupled with massive reductions in […]


    Drop us a line or two. We love to hear from you and are happy to answer any questions.


    5 Parvis Alan Turing
    75013 Paris


    +33 (0)7 68 80 96 52